Literature DB >> 7534798

Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis.

R J Quigg1, V M Holers, B P Morgan, A E Sneed.   

Abstract

Human glomerular epithelial cells (GEC) contain CD59, decay-accelerating factor, and membrane cofactor protein. Crry is the rodent analogue to the latter two proteins. We have previously shown that the nephritogenic Ab of passive Heymann nephritis, anti-Fx1A, impairs C regulation in rat GEC. Here we examined rat GEC C regulation. 125I-labeled GEC membrane proteins were immunoprecipitated with anti-Crry, anti-CD59, or anti-Fx1A. Crry and CD59 were present in GEC. Anti-Fx1A reacted with both Crry and CD59 from GEC, as well as with purified rCrry and CD59. The alternative C pathway was studied by incubating GEC in rat serum in Mg(++)-EGTA buffer. To inhibit the function of the C regulators, anti-Crry or anti-CD59 Ab were added to GEC. Inhibition of CD59 function alone had no effect on C regulation, whereas inhibition of Crry led to significant cytotoxicity from alternative pathway activation. Under conditions in which Crry was inactive, inhibition of CD59 further enhanced cytotoxicity. When the classical pathway of C was activated by GEC-bound IgG Ab, inhibition of either Crry or CD59 enhanced cytotoxicity, whereas inhibition of both Crry and CD59 together was additive. Therefore, Crry and CD59 are present and functionally active in GEC. Crry restricts C activation via both alternative and classical pathways. When the classical pathway of C is activated, or when Crry function is inhibited, CD59 limits C5b-9-mediated cytotoxicity. Anti-Fx1A binds to both Crry and CD59, which may account for its ability to activate the alternative pathway in vitro, and for its superior nephritogenicity in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534798

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

Review 2.  Clinical immunology.

Authors:  T E Mollnes; M Harboe
Journal:  BMJ       Date:  1996-06-08

3.  Mesenchymal stem cells are injured by complement after their contact with serum.

Authors:  Yan Li; Feng Lin
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

4.  Tissue distribution of the rat analogue of decay-accelerating factor.

Authors:  O B Spiller; S M Hanna; B P Morgan
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

5.  Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA.

Authors:  R J Quigg; C F Lo; J J Alexander; A E Sneed; G Moxley
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Mouse CD4+ CD25+ T regulatory cells are protected from autologous complement mediated injury by Crry and CD59.

Authors:  Qing Li; Kristine Nacion; Hong Bu; Feng Lin
Journal:  Biochem Biophys Res Commun       Date:  2009-03-10       Impact factor: 3.575

7.  Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage.

Authors:  Yan Li; Wen Qiu; Lingjun Zhang; John Fung; Feng Lin
Journal:  Biomaterials       Date:  2016-06-08       Impact factor: 12.479

8.  Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells.

Authors:  Silvia Ehrlenbach; Alejandra Rosales; Wilfried Posch; Doris Wilflingseder; Martin Hermann; Jens Brockmeyer; Helge Karch; Simon C Satchell; Reinhard Würzner; Dorothea Orth-Höller
Journal:  Infect Immun       Date:  2013-05-20       Impact factor: 3.441

Review 9.  The role of complement in membranous nephropathy.

Authors:  Hong Ma; Dana G Sandor; Laurence H Beck
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

Review 10.  Complement regulation in renal disease models.

Authors:  Abhijit Naik; Shweta Sharma; Richard J Quigg
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.